Powerful beneficial effects of benfotiamine on cognitive impairment and β-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice

Brain

Volumn 133, Issue 5, 2010, Pages 1342-1351

  Pan, Xiaoli ^a   Gong, Neng ^b   Zhao, Jing ^a   Yu, Zhe ^b   Gu, Fenghua ^c   Chen, Jia ^c   Sun, Xiaojing ^a   Zhao, Lei ^a   Yu, Meijing ^c   Xu, Zhiru ^c   Dong, Wenxin ^c   Qin, Yan ^c   Fei, Guoqiang ^a   Zhong, Chunjiu ^a   Xu, Tian Le ^b  

^a FUDAN UNIVERSITY   (China)

^b Chinese Academy of Sciences   (China)

^c SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY   (China)

Author keywords

Alzheimer's disease; Benfotiamine; Glycogen synthase kinase 3; Thiamine

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BENFOTIAMINE; BETA SECRETASE; FURSULTIAMINE; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; ORGANOPHOSPHATE; PRESENILIN 1; TAU PROTEIN; THIAMINE; THIAMINE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVITY; ENZYME REPRESSION; LIPOPHILICITY; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SPATIAL MEMORY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; CEREBRAL CORTEX; COGNITION; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FURSULTIAMIN; GLYCOGEN SYNTHASE KINASES; ISOENZYMES; MAZE LEARNING; MEMORY; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; PRESENILIN-1; SENILE PLAQUES; SWIMMING; TAU PROTEINS; THIAMINE;

EID: 77951909056     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq069     Document Type: Article

References (40)

1. Alspach JD, Ingraham LL. Inhibition of acetylcholinesterase by thiamine. A structure-function study. J Med Chem 1977; 20: 161-164
2. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61: 661-666
3. Bai DL, Tang XC, He XC. Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease. Curr Med Chem 2000; 7: 355-374
4. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; 1: CD005593.
5. Blanchard V, Moussaoui S, Czech C, Touchet N, Bonici B, Planche M, et al. Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice. Exp Neurol 2003; 184: 247-263
6. Blass JP, Gleason P, Brush D, DiPonte P, Thaler H. Thiamine and Alzheimer's disease. A pilot study. Arch Neurol 1988; 45: 833-835
7. Butterworth RF, Besnard AM. Thiamine-dependent enzyme changes in temporal cortex of patients with Alzheimer's disease. Metab Brain Dis 1990; 5: 179-184
8. Calingasan NY, Gandy SE, Baker H, Sheu KF, Kim KS, Wisniewski HM, et al. Accumulation of amyloid precursor protein-like immunoreactivity in rat brain in response to thiamine deficiency. Brain Res 1995; 677: 50-60.
9. Cullen KM, Halliday GM. Neurofibrillary tangles in chronic alcoholics. Neuropathol Appl Neurobiol 1995; 21: 312-318
10. Gadau S, Emanueli C, Van Linthout S, Graiani G, Todaro M, Meloni M, et al. Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angio-genesis and inhibition of apoptosis. Diabetologia 2006; 49: 405-420
11. Gibson GE, Blass JP. Thiamine-dependent processes and treatment strategies in neurodegeneration. Antioxid Redox Signal 2007; 9: 1605-1619
12. Gibson GE, Sheu KF, Blass JP, Baker A, Carlson KC, Harding B, et al. Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch Neurol 1988; 45: 836-840
13. Gjone E, Hakon Skramstad K. Thiamin and cocarboxylase as inhibitors of cholinesterases. Acta Pharmacol Toxicol (Copenh) 1955; 11: 94-102.
14. Gold M, Hauser RA, Chen MF. Plasma thiamine deficiency associated with Alzheimer's disease but not Parkinson's disease. Metab Brain Dis 1998; 13: 43-53.
15. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9: 294-299
16. Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia. Br J Radiol 2007; 80 (Spec No 2): S160-7.
17. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998; 4: 97-100.
18. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004; 53: 474-481
19. Karuppagounder SS, Xu H, Shi Q, Chen LH, Pedrini S, Pechman D, et al. Thiamine deficiency induces oxidative stress and exacerbates the plaque pathology in Alzheimer's mouse model. Neurobiol Aging 2009; 30: 1587-1600
20. Kennedy AM, Frackowiak RS, Newman SK, Bloomfield PM, Seaward J, Roques P, et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Lett 1995; 186: 17-20.
21. Loew D. Pharmacokinetics of thiamine derivatives especially of benfotia-mine. Int J Clin Pharmacol Ther 1996; 34: 47-50.
22. Lu J, Frank EL. Rapid HPLC measurement of thiamine and its phosphate esters in whole blood. Clin Chem 2008; 54: 901-906
23. Marchetti V, Menghini R, Rizza S, Vivanti A, Feccia T, Lauro D, et al. Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling. Diabetes 2006; 55: 2231-2237
24. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997; 23: 134-147
25. Mastrogiacoma F, Bettendorff L, Grisar T, Kish SJ. Brain thiamine, its phosphate esters, and its metabolizing enzymes in Alzheimer's disease. Ann Neurol 1996; 39: 585-591 (Pubitemid 26143596)
26. Mimori Y, Katsuoka H, Nakamura S. Thiamine therapy in Alzheimer's disease. Metab Brain Dis 1996; 11: 89-94.
27. Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci 2008; 1147: 180-195
28. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-790
29. Nolan KA, Black RS, Sheu KF, Langberg J, Blass JP. A trial of thiamine in Alzheimer's disease. Arch Neurol 1991; 48: 81-83
30. Nozaki S, Mizuma H, Tanaka M, Jin G, Tahara T, Mizuno K, et al. Thiamine tetrahydrofurfuryl disulfide improves energy metabolism and physical performance during physical-fatigue loading in rats. Nutr Res 2009; 29: 867-872
31. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003; 423: 435-439
32. Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, Rose JB, et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phos-phorylation. J Neurosci 2007; 27: 1981-1991
33. Rodriguez-Martin JL, Lopez-Arrieta JM, Qizilbash N. Thiamine for Alzheimer's disease. Cochrane Database Syst Rev 2000; 2: CD001498.
34. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 2005; 7: 63-80.
35. Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 2006; 9: 309-317
36. Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol 2004; 55: 801-814
37. Varkonyi T, Kempler P. Diabetic neuropathy: new strategies for treatment. Diabetes Obes Metab 2008; 10: 99-108.
38. Volvert ML, Seyen S, Piette M, Evrard B, Gangolf M, Plumier JC, et al. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacol 2008; 8: 10.
39. Zhang Q, Yang G, Li W, Fan Z, Sun A, Luo J, et al. Thiamine deficiency increases beta-secretase activity and accumulation of beta-amyloid peptides. Neurobiol Aging 2009. Epub ahead of print.
40. Zhao Y, Pan X, Zhao J, Wang Y, Peng Y, Zhong C. Decreased transke-tolase activity contributes to impaired hippocampal neurogenesis induced by thiamine deficiency. J Neurochem 2009; 111: 537-546